| Patent Number |
Title Of Patent |
Date Issued |
| 7297706 |
Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disor |
November 20, 2007 |
| Compounds of formula (I) ##STR00001## in which R, R.sup.1, R.sup.2, n and X.sup.1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders. |
| 7294627 |
Chemical compounds |
November 13, 2007 |
| Compounds of formula (I) ##STR00001## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4, have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders. |
| 7265127 |
.beta..sub.3 adrenergic agonists |
September 4, 2007 |
| The present invention relates to 2-imidazo[1,2-a]pyridine group containing .beta..sub.3 adrenergic receptor agonists or pharmaceutical salts thereof. |
| 7265121 |
Chemical compounds |
September 4, 2007 |
| Compounds of formula (I) ##STR00001## in which R.sup.1, R.sup.2 and X.sup.4 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders. |
| 7253181 |
.beta..sub.3 adrenergic agonists |
August 7, 2007 |
| The present invention relates to pyrrolopyridine-3-yl group containing .beta..sub.3 adrenergic receptor agonists or pharmaceutical salts thereof. |
| 7241772 |
.beta..sub.3 adrenergic agonists |
July 10, 2007 |
| The present invention relates to 2-imidazo[1,5-a]pyridine containing .beta..sub.3 adrenergic receptor agonists or pharmaceutical salts thereof. |
| 7208505 |
.beta.3 adrenergic agonists |
April 24, 2007 |
| The present invention relates to a .beta.3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity ##STR00001## |
| 7205407 |
3-Substituted oxindole .beta.3 agonists |
April 17, 2007 |
| The present invention relates to a .beta.3 adrenergic receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity ##STR00001## |
| 7160909 |
Cyclopenta[b]indole derivatives as sPLA.sub.2 inhibitors |
January 9, 2007 |
| A novel class of tricyclic compounds of the following formula (I) is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 7122680 |
3-Substituted oxindole .beta..sub.3 agonsists |
October 17, 2006 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula I: ##STR00001## or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity. |
| 7115609 |
Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases |
October 3, 2006 |
| Compounds of formula (I) ##STR00001## in which R.sup.1, R.sup.2, n and X.sup.1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders. |
| 7109231 |
Cyclohept[b]indole derivatives |
September 19, 2006 |
| A novel class of tricyclic compounds of the following formula (I): (formula I); is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock ##STR00001## |
| 7087635 |
3-substituted oxindole .beta.3 agonists |
August 8, 2006 |
| The present invention relates to a .beta.3 adrenergic receptor agonist of formula I: ##STR00001## or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. |
| 7078415 |
Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disor |
July 18, 2006 |
| Compounds of formula (I) ##STR00001## in which R, R.sup.1, R.sup.2, n and X.sup.1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders. |
| 7071208 |
.beta..sub.3 Adrenergic agonists |
July 4, 2006 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity. |
| 6992100 |
sPLA.sub.2 inhibitors |
January 31, 2006 |
| A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6974831 |
sPLA2 inhibitors |
December 13, 2005 |
| A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6930123 |
sPLA2 inhibitors |
August 16, 2005 |
| A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6916840 |
Spla2 inhibitors |
July 12, 2005 |
| A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6911463 |
3-substituted oxindole .beta.-3 agonists |
June 28, 2005 |
| The present invention relates to a .beta.3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. |
| 6872743 |
sPLA2 inhibitors |
March 29, 2005 |
| A novel class of tetracyclic compounds represented by the formula I ##STR1##wherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Dise |
| 6825220 |
3-Substituted oxindole .beta. 3 agonists |
November 30, 2004 |
| The present invention relates to a .beta.;3 adrenergic receptor agonist of formula I: (1); or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity. |
| 6730792 |
.beta.3 adrenergic agonists |
May 4, 2004 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can a |
| 6713645 |
Substituted tricyclics |
March 30, 2004 |
| A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock. |
| 6620837 |
Antithrombotic agents |
September 16, 2003 |
| This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of defined compounds |
| 6448284 |
Substituted tricyclics |
September 10, 2002 |
| A class of tricycles is disclosed together with the use of such for inhibiting Spla.sub.2 mediated release of fatty acids for the treatment of conditions such as septic shock. |
| 6359136 |
Antithrombotic agents |
March 19, 2002 |
| This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formu |
| 6274578 |
sPLA2 inhibitor ester |
August 14, 2001 |
| The compound, ((3(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)ac etic acid N-morpholino ester, is disclosed together with its use as a highly bioavailable indole sPLA.sub.2 inhibitor compound. |
| 6265416 |
Antithrombotic agents |
July 24, 2001 |
| This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formu |
| 6251921 |
Antithrombotic diamines |
June 26, 2001 |
| This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulati |
| 6177440 |
Substituted tricyclics |
January 23, 2001 |
| A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock. |
| 6140327 |
Morpholino-n-ethyl ester derivative of an indole sPLA.sub.2 inhibitor |
October 31, 2000 |
| The compound, ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)ac etic acid morpholino-N-ethyl ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of condition |
| 6133262 |
Antithrombotic agents |
October 17, 2000 |
| This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formu |
| 6025382 |
Antithrombotic diamines |
February 15, 2000 |
| This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulati |
